Press release

Accenture Introduces INTIENT™, an Innovative Platform to Advance the Discovery, Development and Delivery of Patient Treatments

Sponsored by Businesswire

Accenture (NYSE: ACN) today introduced INTIENT™,
a technology platform that vastly improves the continuity and flow of
data across life sciences enterprises, supporting the delivery of
ground-breaking treatments for patients.

This press release features multimedia. View the full release here:

Copyright © 2019 Accenture. All rights reserved.

Copyright © 2019 Accenture. All rights reserved.

Building upon Accenture’s market-proven platforms for research, clinical
development, pharmacovigilance and patient services, INTIENT enables the
rapid integration of new technology, and advanced analytics powered by Accenture
Applied Intelligence

Designed with an open architecture, Accenture INTIENT will help life
sciences companies advance:

  • Data security, through compliant data ingestion, storage and
  • The application of artificial intelligence and advanced analytics –
    including robotic process automation and machine learning – to provide
    novel and actionable insights;
  • Collaboration across the enterprise, unifying functional teams with
    common data insights and metrics;
  • Access to an external partner network, removing barriers to entry for
    technology, data and service providers; and
  • Productivity through more efficient, streamlined technology systems.

Accenture INTIENT addresses a clear need within the life sciences
industry. A recent survey by IDC Health Insights*, found that more than
98% of 126 pharmaceutical and biotechnology executives said that the
ability to use data from other functional areas was important or very
important to achieving their company’s business strategy, and that 94%
said the same of the ability to apply advanced analytics and/or
artificial intelligence to data from across the organization.

IDC’s survey also revealed a critical disconnect that INTIENT will help
to address: Although three-quarters (75%) said that improving their
ability to connect, share and analyze data from across the organization
is critical to their company’s success, more than half (51%) said they
do not have a clear path toward achieving that goal.

“Important insights that could lead to the discovery, development and
delivery of promising new treatments are too often trapped within the
functional silos of pharmaceutical and biotechnology companies,” said Kevin
, a senior managing director in the Accenture Life Sciences
practice. “With INTIENT, our clients will be able to generate insights
from research through to patient services, and even further with our
plans to expand into other functions. The results will accelerate the
delivery of life-changing treatments to patients.”

, Ph.D., research director for Life Sciences at IDC Health
Insights, said, “In this recent survey, and in IDC’s industry analysis,
we can see that life sciences companies understand the benefits of
implementing more connected, capable technology systems, yet have
limited agreement on the best path forward to solve this challenge.
Clearly, there is work to do for the industry to realize the potential
of end-to-end connectivity, and solutions such as Accenture INTIENT
could prove to be a step forward in those efforts.”

In addition to offering unique connectivity and capabilities, INTIENT
also includes these established platforms:

  • Accenture INTIENT Research
    : This platform, previously known as the
    Accenture research platform, connects researchers with software and
    service providers to share data and capabilities to rapidly advance
    scientific discovery.
  • Accenture INTIENT Clinical
    : Previously known as the Accenture Life Sciences
    Cloud, this platform enables the capture, storage, import and
    standardization of complex data to help clinical development teams run
    faster, more transparent clinical trials.
  • Accenture INTIENT Pharmacovigilance
    : Previously named PV First, this platform
    embeds real-time artificial intelligence, machine learning and
    advanced operational and scientific analytics to each step of the
    pharmacovigilance process, from case intake to regulatory reporting
    and distribution.
  • Accenture INTIENT Patient
    : This platform, previously called the
    Intelligent Patient Platform, helps life sciences companies better
    support patients from clinical trials through ongoing treatment and

Learn more about Accenture INTIENT.

* IDC Survey, sponsored by Accenture, The Case for Connectivity in
the Life Sciences, 2019

About Accenture

Accenture is a leading global professional services company, providing a
broad range of services and solutions in strategy, consulting, digital,
technology and operations. Combining unmatched experience and
specialized skills across more than 40 industries and all business
functions — underpinned by the world’s largest delivery network —
Accenture works at the intersection of business and technology to help
clients improve their performance and create sustainable value for their
stakeholders. With 477,000 people serving clients in more than 120
countries, Accenture drives innovation to improve the way the world
works and lives. Visit us at

Accenture Applied Intelligence, part of Accenture
, applies artificial intelligence and human ingenuity at the
core of business to help clients solve their most complex business
problems. By deploying AI responsibly and combining it with our deep
industry and analytics expertise, we enable the digital transformation
of organizations, extend human capabilities, and make intelligent
products and services a reality. Follow @AccentureAI and